News & Views
DefiniGEN to Invest in new Stem Cell Lines
Jun 24 2016
Life sciences products provider DefiniGEN has raised £1.5m ($2.29m) in follow-on funding that will support development of new pancreatic and lung stem cells for drug discovery and regenerative medicine. The round was led by Cambridge Enterprise, the commercialisation arm of the University of Cambridge, and 24 Haymarket, with key investors Dr Jonathan Milner (Chairman), Providence Investment Company, Parkwalk, and Cambridge Capital Group also participating. This funding follows the closing of £2.28 million ($3.83 million) Series A funding in 2014.
The company’s platform technology OptiDIFF produces cell types that can be used as predictive in vitro models to support the development of safer and more effective treatments for disease ahead of clinical trials. The new funding will also support the company’s business expansion in North America, Europe and Asia Pacific, the funding of new staff and scale-up of production facilities.
Commenting on the announcement, Dr Marcus Yeo, CEO of DefiniGEN said: “In a short space of time, DefiniGEN has undergone rapid development, securing growing sales with global pharma companies. We are delighted to have raised the funds that will allow us to deliver new market-leading products to our customers and assist them in developing therapies for the global healthcare challenges we face today such as diabetes and liver disease.”
Digital Edition
International Labmate Buyers' Guide 2024/25
June 2024
Buyers' Guide featuring: Product Listings & Manufacturers Directory Chromatography Articles - Enhancing HPLC Field Service with fast-response, non-invasive flowmeters - Digital transformatio...
View all digital editions
Events
Jul 20 2024 Denver, CO, USA
Jul 21 2024 Cape Town, South Africa
Jul 28 2024 San Diego, CA USA
Jul 30 2024 Jakarta, Indonesia
Jul 31 2024 Chengdu, China